论文部分内容阅读
洛萨坦(Losartan)可以保护糖尿病患者免于因心律失常而发生突然心源性死亡,其效果要好于阿坦洛(Atenolol)。 瑞典Ume大学医院的Dr Lars H.Lindholm及其同事以前曾发现,在糖尿病患者中,以洛萨坦为主的抗高血压治疗能降低所有原因引起的死亡率,其效果优于阿坦洛。他们使用了合并高血压和左心室肥大的糖尿病患者资料,以检查急性心源性死亡比例。 研究人员对1,195名患者进行了至少4年的随诊观察。结果发现:在洛萨坦组中,急性心脏病的死亡率为5.0/1000病人年,而阿坦洛组则为10.7。两组间的这一显著差异与导致急性心脏病死亡的其他原因无关。
Losartan protects diabetics from sudden cardiac death due to arrhythmia, which is better than Atenolol. Dr Lars H. Lindholm and colleagues at Ume University Hospital in Sweden have previously found that losartan-based antihypertensive treatment can reduce all-cause mortality in patients with diabetes, outperforming atazanil. They used data on patients with diabetes mellitus and left ventricular hypertrophy to check the percentage of acute cardiac deaths. The researchers conducted 1,195 patients for at least 4 years of follow-up. The results showed that: in the losartan group, the mortality rate of acute heart disease was 5.0 / 1000 patient-year, while that of the atanal group was 10.7. This significant difference between the two groups has nothing to do with other causes of death from acute cardiac disease.